DAFIDA
DEAD

Serial Number

87174403

Owner

ACTAVIS HOLDCO US, INC.

Filing Date

Sep 16, 2016

Add to watchlist:

No watchlists yet
View on USPTO

DAFIDA Trademark

Serial Number: 87174403

DAFIDA is a trademark filed by ACTAVIS HOLDCO US, INC. on September 16, 2016. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

ACTAVIS HOLDCO US, INC. (65 trademarks)

PARSIPPANY, NJ 07054

Entity Type: 03

ALLERGAN SALES, LLC (490 trademarks)

5 GIRALDA FARMS
MADISON, NJ 07940

Entity Type: 16

Trademark Details

Filing Date

September 16, 2016

Registration Date

Not Registered

Published for Opposition

January 31, 2017

Goods & Services

Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting urogenital organs; Pharmaceuticals and medicines affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure diseases and disorders; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; Pharmaceuticals, namely, neuroprotective agents; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical preparations for skin care used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatories, anti-infectives, anti-glaucoma eye drops and decongestant formulations; sterile ointments for medical use; ocular wetting solutions, artificial tears and formulations pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, skin rejuvenators, rehydrating creams, and lotions for the face and body

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jun 3, 2020 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jun 2, 2020 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 17, 2019 EXRA
SOU EXTENSION 5 GRANTED
Jul 16, 2019 EX5G
SOU EXTENSION 5 FILED
Jul 11, 2019 EXT5
SOU TEAS EXTENSION RECEIVED
Jul 11, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 28, 2019 EXRA
SOU EXTENSION 4 GRANTED
Mar 26, 2019 EX4G
SOU EXTENSION 4 FILED
Mar 26, 2019 EXT4
SOU TEAS EXTENSION RECEIVED
Mar 26, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 19, 2018 EXRA
SOU EXTENSION 3 GRANTED
Sep 17, 2018 EX3G
SOU EXTENSION 3 FILED
Sep 17, 2018 EXT3
SOU TEAS EXTENSION RECEIVED
Sep 17, 2018 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 20, 2018 EXRA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 16, 2018 TCCA
SOU EXTENSION 2 GRANTED
Feb 16, 2018 EX2G
SOU EXTENSION 2 FILED
Feb 16, 2018 EXT2
SOU TEAS EXTENSION RECEIVED
Feb 16, 2018 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 13, 2017 EXRA
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Sep 12, 2017 AITU
SOU EXTENSION 1 GRANTED
Sep 11, 2017 EX1G
SOU EXTENSION 1 FILED
Sep 11, 2017 EXT1
SOU TEAS EXTENSION RECEIVED
Sep 11, 2017 EEXT
FAX RECEIVED
Aug 18, 2017 FAXX
SOU TEAS EXTENSION RECEIVED
Aug 16, 2017 EEXT
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jul 5, 2017 ASGN
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 28, 2017 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 31, 2017 NPUB
PUBLISHED FOR OPPOSITION
Jan 31, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 11, 2017 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 22, 2016 CNSA
ASSIGNED TO EXAMINER
Dec 21, 2016 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 21, 2016 NWOS
NEW APPLICATION ENTERED
Sep 20, 2016 NWAP